Therefore, we focussed on ACPA and IgM-RF levels at baseline and changes in the year thereafter in relation to outcome at two years, to investigate whether this would provide additional prognostic information in early arthritis patients. The gene discussed is PRTN3; the disease is arthritic joint disease.